Polskie Archiwum Medycyny Wewnętrznej · 2022 · 20 citations · 37 references
MedicinePharmacologyPharmacotherapyCardiovascular PharmacotherapyClinical PharmacologyMolecular PharmacologyInsulin ResistanceMetabolic SyndromeObesity ManagementObesity PharmacotherapySodium-glucose Cotransporter 2 InhibitorsWeight ManagementAntidiabetic Drug TherapyCardiometabolic DiseaseGlucose-lowering TherapyObesity TreatmentRenal Glucose ReabsorptionSodium-glucose Cotransporter 2 InhibitionType 2 Diabetes PharmacotherapyType 2 Diabetes Treatment
As the tide of obesity and its complications are on the rise, there is an urgent need for new drugs with weight‑lowering and beneficial metabolic properties. Obesity‑related disorders, such as metabolic syndrome, prediabetes, type 2 diabetes (T2D), cardiovascular disease, and nonalcoholic fatty liver disease (NAFLD) make this need more than mandatory. Sodium‑glucose cotransporter‑2 (SGLT‑2) inhibitors (empagliflozin, canagliflozin, dapagliflozin, and ertugliflozin) are the latest class of agents to receive approval for the treatment of T2D. Not long after their marketing, a wide spectrum of target organ‑protective and overall beneficial health effects associated with their use began to unveil. An increasing bulk of evidence indicates that these actions are to a great degree independent of glucose lowering, which has led to the broadening of the indications for SGLT‑2 inhibitors outside the frame of antihyperglycemic therapy. Additionally, their unique mode of action including increased renal glucose excretion, and hence net energy loss, could render SGLT‑2 inhibitors attractive candidates for the treatment of obesity. Very few reviews in the literature have holistically appraised the therapeutic potential of SGLT‑2 inhibitors in obesity and its associated complications. Herein, we summarize the currently available evidence regarding the effects of drugs of this class on body adiposity, together with considerations on their potential use as weight loss agents. Furthermore, we attempt to overview their actions and future perspectives of their use with respect to a range of obesity‑related disorders, which include cardiovascular, renal, and ovarian dysfunctions, as well as NAFLD and malignancy.
37
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman, Christoph Wanner, John M. Lachin et al. · New England Journal of Medicine · 2015 · 12K citations · Full text
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal, Vlado Perkovic, Kenneth W. Mahaffey et al. · New England Journal of Medicine · 2017 · 7.8K citations · Full text
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Stephen D. Wiviott, Itamar Raz, Marc P. Bonaca et al. · New England Journal of Medicine · 2018 · 6.3K citations · Full text
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Vlado Perkovic, Meg Jardine, Bruce Neal et al. · New England Journal of Medicine · 2019 · 6K citations · Full text
Medicine, Nephrology, Pharmacology +17